Cracking the Marketing Conversion Barrier
The Christie Conversion CodeBreak™ Methodology transforms consumer insight-driven marketing for Better Results SANTA BARBARA, Calif., Dec. 30, 2024 /PRNewswire/ — Ad budgets and results continue to diminish with the substitution of AI marketing as they often lack that core emotional conne
" title="Shamikhat Al-Sheqah, owned by Ibrahim Al-Muhaidib, Claims Al-Shaddad Award and the Title of “Munqiyat Al-Jazeera”
Heritage Meets Innovation: ‘Shamikhat Al-Sheqah’ Soars with Al-Shaddad Award and Claims the Title of ‘Munqiyat Al-Jazeera’ RIYADH, Saudi Arabia, Dec. 30, 2024 /PRNewswire/ — Amid an atmosphere brimming with excitement and anticipation, in a historic evening, Ibrahim bi
WuXi AppTec’s Commitment to Sustainability Recognized by the Dow Jones Sustainability Indices (DJSI) for the Fourth Consecutive Year
SHANGHAI, Dec. 30, 2024 /PRNewswire/ — WuXi AppTec, a global company that provides a broad portfolio of R&D and manufacturing services to enable companies in the pharmaceutical and life science industries, announced that it has been recognized by the prestigious Dow Jones Sustainability I
Halozyme Announces Takeda Received Regulatory Approval for HYQVIA® 10% Subcutaneous Injection Set with ENHANZE® in Japan for Patients with Agammaglobulinemia or Hypogammaglobulinemia
SAN DIEGO, Dec. 30, 2024 /PRNewswire/ — Halozyme Therapeutics, Inc. (NASDAQ: HALO) (Halozyme) today announced that Takeda received regulatory approval for HYQVIA® [Immune Globulin Infusion 10% (Human) with Halozyme’s Recombinant Human Hyaluronidase] by the Japanese Ministry of Health, L
Vectra AI Positioned as a Leader in the 2024 SPARK Matrix™ for Network Detection and Response by QKS Group
The QKS Group SPARK Matrix™ provides competitive analysis and ranking of the leading Network Detection and Response vendors. Vectra AI, with its comprehensive technology and customer experience management, has received strong ratings across the parameters of technology excellence and customer impa
China’s role in economic globalization
BEIJING, Dec. 30, 2024 /PRNewswire/ — A report from China Daily: Economic globalization has brought development opportunities to the world and improved the lives of billions of people around the globe. As the world’s second-largest economy, the largest trading country and the second-lar
Target Hospitality Advances Growth Priorities with Strategic Hire
THE WOODLANDS, Texas, Dec. 30, 2024 /PRNewswire/ — Target Hospitality Corp. (“Target Hospitality,” “Target” or the “Company”) (Nasdaq: TH), one of North America’s largest providers of vertically integrated modular accommodations and value-added hospita
Halozyme Announces argenx’s VYDURA with ENHANZE® was Granted Regulatory Approval in Japan for Chronic Inflammatory Demyelinating Polyneuropathy
SAN DIEGO, Dec. 30, 2024 /PRNewswire/ — Halozyme Therapeutics, Inc. (NASDAQ: HALO) (Halozyme) today announced that argenx’s VYVDURA (efgartigimod alfa and hyaluronidase-qvfc), which is co-formulated with Halozyme’s ENHANZE® drug delivery technology, was granted regulatory approval
Halozyme Announces FDA Approval of Bristol Myers Squibb’s Opdivo Qvantig™ with ENHANZE® for Subcutaneous Use in Most Previously Approved Adult Solid Tumor Opdivo® (nivolumab) Indications
Opdivo Qvantig represents the first and only subcutaneously administered PD-1 inhibitor Opdivo Qvantig demonstrated consistent efficacy and showed a comparable safety profile to IV Opdivo in the Phase 3 CheckMate-67T trial SAN DIEGO, Dec. 30, 2024 /PRNewswire/ — Halozyme Therapeutics, Inc. (NA
CELH INVESTOR ALERT: Celsius Holdings, Inc. Investors with Substantial Losses Have Opportunity to Lead Securities Class Action Lawsuit
SAN DIEGO, Dec. 30, 2024 /PRNewswire/ — Robbins Geller Rudman & Dowd LLP announces that purchasers of Celsius Holdings, Inc. (NASDAQ: CELH) common stock between February 29, 2024 and September 4, 2024, both dates inclusive (the “Class Period”), have until Tuesday, January 21, 2
